Citigroup Inc Surface Oncology, Inc. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$0.57 - $0.88 $574,845 - $887,480	-1,008,500 Reduced 96.4%	37,657 $32,000
Q4 2022 Feb 09, 2023	SELL	$0.62 - $1.21 $381 - $744	-615 Reduced 0.06%	1,046,157 $857,000
Q3 2022 Nov 10, 2022	SELL	$1.05 - $2.1 $426 - $852	-406 Reduced 0.04%	1,046,772 $1.09 Million
Q2 2022 Aug 10, 2022	BUY	$1.42 - $3.15 $1.48 Million - $3.29 Million	1,044,658 Added 41454.68%	1,047,178 $1.72 Million
Q1 2022 May 12, 2022	SELL	$2.65 - $5.08 $21,287 - $40,807	-8,033 Reduced 76.12%	2,520 $7,000
Q4 2021 Feb 10, 2022	BUY	$4.73 - $7.9 $19,255 - $32,160	4,071 Added 62.8%	10,553 $50,000
Q3 2021 Nov 10, 2021	BUY	$5.16 - $7.98 $33,447 - $51,726	6,482 New	6,482 $49,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.